The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Editorial

The Three R's: Radiation for Restenotic Renals?

Authors: John P. Reilly, MD, Joseph Kaminski, MD, James B. Summers, MD, MS

Abstract

Revascularization of renal artery stenosis in an effort to control hypertension and preserve renal function is becoming more widely accepted. Peripheral intervention of atherosclerotic renal arteries by balloon angioplasty with stenting is the preferred means of revascularization. Stenting induces a proliferative response, sometimes producing enough neointimal hyperplasia within the lumen of the stent to obstruct flow. The incidence of in-stent restenosis (ISR) in renal arteries is approximately 20%. 1 As equipment and techniques continue to improve, the number of patients diagnosed with and managed for ISR of renal arteries will increase. I

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lederman RJ, Mendelsohn FO, Santos R, et al. Primary renal artery stenting: Characteristics and outcomes after 363 procedures. Am Heart J 2001; 142: 314–323.
 
2. Jahraus CD, St Clair W, Gurley J, et al. Endovascular brachytherapy for the treatment of renal artery in-stent restenosis using a β-emitting source: A report of five patients. South Med J 2003; 96: 1165–1168.
 
3. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary γ-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250–256.
 
4. Suntharalingam M, Laskey W, Lansky AJ, et al. Clinical and angiographic outcomes after use of90strontium/90yttrium β radiation for the treatment of in-stent restenosis: Results from the Stents and Radiation Therapy 40 (START 40) registry. Int J Radiat Oncol Biol Phys 2002; 52: 1075–1082.
 
5. Waksman R, Raizner AE, Yeung AC, et al. Use of localised intracoronary β radiation in treatment of in-stent restenosis: The INHIBIT randomised controlled trial. Lancet 2002; 359: 551–557.
 
6. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697–1703.
 
7. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999; 100: 1872–1878.
 
8. Ho KK. Predictors of angiographic restenosis after stenting: Pooled analysis of 1197 patients with protocol-mandated angiographic follow-up from five randomized stent trials. Circulation 1998; 97( Suppl I): 362(abstract).
 
9. Lufft V, Hoogestraat-Lufft L, Fels LM, et al. Contrast media nephropathy: Intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis—a prospective randomized trial. Am J Kidney Dis 2002; 40: 236–242.
 
10. Amols HI, Zaider M, Weinberger J, et al. Dosimetric considerations for catheter-based β and γ emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys 1996; 36: 913–921.
 
11. Hall EJ. The physics and chemistry of radiation absorption, in Hall EJ: Radiobiology for the Radiologist. Philadelphia, J.B. Lippincott Co., 1994, ed 4, pp 1–13.
 
12. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38–42.
 
13. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107: 24–27.
 
14. Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993; 55: 1409–1418.
 
15. Leon M, Moses J, Popma J, et al. A multicenter randomized clinical study of the sirolimus-eluting stent in native coronary lesions: Angiographic results. Circulation 2002; 106( Suppl II): 393(abstract).
 
16. Stoeteknuel-Friedli S, Do DD, von Briel C, et al. Endovascular brachytherapy for prevention of recurrent renal in-stent restenosis. J Endovasc Ther 2002; 9: 350–353.